Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 5Nivolumab 3Cisplatin 3Taxes 2Paclitaxel 2poly ICLC 1fludarabine phosphate 1fludarabine 1abemaciclib 1Risk Factors 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Pemetrexed 1Nimorazole 1Injections 1High-Intensity Focused Ultrasound Ablation 1Erlotinib Hydrochloride 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biological Products 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Risk Factors × 1 year × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡